News und Analysen
Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use
Transgene Appoints Gaëlle Stadtler as Director of Human Resources
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the appointment of Gaëlle Stadtler as
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
VALBIOTIS kündigt Teilnahme an der 39. jährlichen J.P. Morgan Healthcare Conference und der H.C. Wainwright BioConnect vom 11. bis 14. Januar 2021 im virtuellen Format an
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung
VALBIOTIS Announces Its Participation in the 39th J.P. Morgan Healthcare Annual Conference as well as in H.C. Wainwright BioConnect from January 11-14, 2021, in Virtual Format
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating
EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary
Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a “Buy” Recommendation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021
Lyon, December 28, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
EOS imaging Announces Its Financial Agenda For 2021
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
Nanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP ANNOUNCE THE CREATION AND FUNDING OF NEW JOINT PUBLIC/PRIVATE LABORATORY "NEUROIMAGING FOR DRUG DISCOVERY" (NI2D)
The laboratory obtained funding of €350,000 from the French National Research Agency (ANR).
Lyon, 18 December 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of
Transgene Announces Financial Calendar for 2021
Regulatory News
Transgene (Paris:TNG) today announced its financial reporting dates for 2021:
March 10, 2021:
2020 Fiscal Year Results
April 27, 2021:
First
Transgene Announces Investor Meetings for January 2021
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional
Quantum Genomics Signs a Strategic Contract with Delpharm
Delpharm Group selected for large-scale production of firibastat tablets to support clinical phase and future commercial needs
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a
NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
Regulatory News:
Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales
Faran to receive an exclusive license to develop and commercialize firibastat
Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the "Company" or "GenSight"), a biopharma company focused on developing and
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer